NovaMedica is in advanced negotiations to secure Russia and CIS rights for a wide range of innovative Products. We are seeking specialty pharmaceutical drugs and devices from various potential US and European partners (including Domain Associates, Inc. portfolio companies) spanning several high-growth therapeutic areas in hospital inpatient, hospital outpatient and specialty care clinical contexts. Products can be both FDA/EMA approved and phase 2B/3 late-stage development. Please check back regularly as we grow our pipeline to serve this exciting market.
NovaMedica will produce migraine drug Relonova in Moscow
23 March 2023
A resource for anti-tumor drugs testing has been launched in Russia
23 March 2023
Building a Community of Trust in Epilepsy & Rare Syndromes
23 March 2023
22 March 2023